SCHEMBL7070939

SCHEMBL7070939

NC(=O)N(c1ccc(-c2csc3ncnc(N)c23)c(Cl)c1)c1cc(C(F)(F)F)ccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 9/20 0.50
FLT3 P36888 8/20 0.50
FLT1 P17948 7/20 0.50
LCK P06239 6/20 0.50
CSF1R P07333 6/20 0.50
FGFR1 P11362 5/20 0.50
RET P07949 5/20 0.50
GSK3B P49841 5/20 0.50
MAP4K4 O95819 4/20 0.50
ABL1 P00519 4/20 0.50
NTRK1 P04629 4/20 0.50
CLK2 P49760 4/20 0.50
RPS6KA3 P51812 4/20 0.50
MAP4K2 Q12851 4/20 0.50
ROCK1 Q13464 4/20 0.50
DYRK1A Q13627 4/20 0.50
NTRK2 Q16620 4/20 0.50
TAOK1 Q7L7X3 4/20 0.50
CLK4 Q9HAZ1 4/20 0.50
AURKA O14965 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090597 0.92 KIT (0.52) KITFLT3FLT1LCKCSF1R
SCHEMBL20816501 0.88 FLT1 (0.62) KITFLT3FLT1LCKCSF1R
SCHEMBL29923744 0.88 FLT1 (0.62) KITFLT3FLT1LCKCSF1R
SCHEMBL7131259 0.82 FLT1 (0.59) KITFLT3FLT1LCKCSF1R
SCHEMBL6647235 0.81 KDR (0.51) KITFLT3FLT1LCKCSF1R
SCHEMBL7071304 0.80 KDR (0.54) KITFLT3FLT1LCKCSF1R
SCHEMBL7072125 0.80 KDR (0.56) KITFLT3FLT1LCKCSF1R
SCHEMBL6646551 0.77 KIT (0.53) KITFLT3FLT1LCKCSF1R
SCHEMBL4478281 0.76 KIT (0.78) KITFLT3FLT1LCKCSF1R
SCHEMBL4479348 0.74 KDR (0.50) KITFLT3FLT1LCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KIT 394/4885FLT3 29/4885FLT1 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.